ArticleFrontiers in microbiology2018
Perspectives of Phage Therapy in Non-bacterial Infections.
Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 62 citations in OpenAlex.
- Expanding the Antimicrobial Toolbox with Therapeutic Viruses: Mechanisms, Pharmaceutical Formulation, and Translational Outlook.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Antibiotic Resistance ofPharmaceuticals (Basel, Switzerland) · 2025Review
- Lytic bacteriophages induce the secretion of antiviral and proinflammatory cytokines from human respiratory epithelial cells.PLoS biology · 2024Article
- Lytic bacteriophages interact with respiratory epithelial cells and induce the secretion of antiviral and proinflammatory cytokines.bioRxiv : the preprint server for biology · 2024Article
- Expanding known viral diversity in the healthy infant gut.Nature microbiology · 2023Article
- The Role of the Cutaneous Mycobiome in Atopic Dermatitis.Journal of fungi (Basel, Switzerland) · 2022Review
- Gut bacteria, bacteriophages, and probiotics: Tripartite mutualism to quench the SARS-CoV2 storm.Microbial pathogenesis · 2022Review
- A Thorough Synthesis of Phage Therapy Unit Activity in Poland-Its History, Milestones and International Recognition.Viruses · 2022Article
- Considerations for the Use of Phage Therapy in Clinical Practice.Antimicrobial agents and chemotherapy · 2022Review
- Virus-related Knowledge in Covid-19 Times - Results from two Cross-sectional Studies in Austria and Implications for School.International journal of biological sciences · 2022Article
- Phage derived lytic peptides, a secret weapon againstFrontiers in medicine · 2022Article
- Crosstalk between the Intestinal Virome and Other Components of the Microbiota, and Its Effect on Intestinal Mucosal Response and Diseases.Journal of immunology research · 2022Review
- Gut Microbes and Eye Disease.Ophthalmic research · 2022Review
- Phage therapy in the Covid-19 era: Advantages over antibiotics.Current research in microbial sciences · 2022Review
- Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.Biomolecules · 2021Review
- Clinical Characteristics and Outcomes of Fungal Keratitis in the United Kingdom 2011-2020: A 10-Year Study.Journal of fungi (Basel, Switzerland) · 2021Article
- Microbial Interkingdom Biofilms and the Quest for Novel Therapeutic Strategies.Microorganisms · 2021Review
- Anti-phage serum antibody responses and the outcome of phage therapy.Folia microbiologica · 2021Article
- Gut microbiota in human metabolic health and disease.Nature reviews. Microbiology · 2021Review
- Phages in the fight against COVID-19?Future microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While the true value of phage therapy (PT) in human bacterial infections still awaits formal confirmation by clinical trials, new data have been accumulating indicating that in the future PT may be applied in the treatment of non-bacterial infections. Thus, "phage guests" may interact with eukaryotic cells and such interactions with cells of the immune system may protect human health (Guglielmi, 2017) and cause clinically useful immunomodulatory and anti-inflammatory effects when administered for therapeutic purposes (Górski et al., 2017; Van Belleghem et al., 2017). Recently, a vision of how these effects could translate into advances in novel means of therapy in a variety of human pathologies secondary to immune disturbances and allergy was presented (Górski et al., 2018a). In this article we present what is currently known about anti-microbial effects of phage which are not directly related to their antibacterial action and how these findings could be applied in the future in treatment of viral and fungal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.